Buchang Pharmaceutical announced that since shares in the special account are not entitled to profit distribution rights to repurchase, the company will implement differentiated dividends for the 2025 annual profit distribution. In January and May 2026, the company completed two separate share repurchases, with a total of 16,678,396 shares repurchased. At the end of the fiscal year 2025, it is proposed to distribute a cash dividend of 1.80 yuan for every 10 shares, based on the total share capital registered on the share registration date of implementing equity distribution and repurchase of shares. There will be no transfer or share transfer. Based on the closing price of the trading day prior to the application date, the differentiated equity distribution has less impact on the exclusion ex-dividend reference price.

Buchang Pharmaceutical announced that since shares in the special account are not entitled to profit distribution rights to repurchase, the company will implement differentiated dividends for the 2025 annual profit distribution. In January and May 2026, the company completed two separate share repurchases, with a total of 16,678,396 shares repurchased. At the end of the fiscal year 2025, it is proposed to distribute a cash dividend of 1.80 yuan for every 10 shares, based on the total share capital registered on the share registration date of implementing equity distribution and repurchase of shares. There will be no transfer or share transfer. Based on the closing price of the trading day prior to the application date, the differentiated equity distribution has less impact on the exclusion ex-dividend reference price.